Lumida
/ANAB
⌘K
AnaptysBio Inc

AnaptysBio Inc

ANAB
$53.87USD-2.34%-1.29 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$54 – $56

52W RANGE

$17
$73

AI Summary

Stalk
Sell NowMedium

ANAB exhibits a bearish continuation of lower highs and lows, trading below declining EMAs and a modestly lower 200-day SMA. The medium-term bias is bearish, confirmed by volume-heavy down-days, while the short term favors selling into the current weakness around the recent low. Primary risk is a sharp oversold bounce or failure to break 200-day SMA support, which would stall the downtrend.

  • Proprietary platform advancing imsidolimab for GPP creates key pipeline catalyst.
  • 3.72% yield offers income buffer amid biotech volatility.
  • Expected Q2 EPS of −$0.22 underscores persistent unprofitability.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$63.2M$10.3M$17.2M$91.3M$234.6M
YoY %-15.8%-83.7%+66.8%+432.0%+157.0%
P / Sales15.1x80.0x34.1x4.1x5.9x
EV / Sales11.8x106.9x53.2x7.3x6.3x
Gross Profit, Adj.$63.2M$10.3M$17.2M$91.3M$234.6M
YoY %-15.8%-83.7%+66.8%+432.0%+157.0%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit11.8x106.9x53.2x7.3x6.3x
EBITDA, Adj.$-54.7M$-114.5M$-156.4M$-114.3M$48.5M
YoY %-134.7%-109.2%-36.6%+26.9%+142.4%
Margin %-86.6%-1112.9%-911.7%-125.3%20.7%
EV / EBITDA-13.6x-9.6x-5.8x-5.8x30.6x
EBIT$-56.8M$-115.2M$-164.4M$-114.9M$47.9M
YoY %-137.9%-102.7%-42.8%+30.1%+141.7%
Margin %-89.9%-1119.4%-958.3%-125.9%20.4%
EV / EBIT-13.1x-9.6x-5.6x-5.8x31.0x
Net Income$-57.8M$-128.7M$-163.6M$-145.2M$-13.2M
YoY %-190.0%-122.7%-27.1%+11.2%+90.9%
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (GAAP)-$2.11-$4.57-$6.08-$5.12-$0.46
YoY %-189.0%-116.6%-33.0%+15.8%+91.0%